首页> 外文期刊>Medicine. >A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report
【24h】

A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report

机译:高度恶性的神经母细胞瘤病例,单核苷酸变异和正常错配修复系统大量增加:病例报告

获取原文
           

摘要

Rationale: Neuroblastoma is a common abdominal malignancy in children. The chemoresistant and relapsed cases have poor prognosis. The genetic background and the mechanism of resistance remain unelucidated. Next-generation sequence (NGS) is becoming a popular tool to unravel the genetic background and to guide precision medicine in oncology studies as well as in clinical practice. Patient concerns: Here we report a neuroblastoma case of a boy aged 2 years and 8 months when first diagnosed, with multiple metastatic sites found in both lungs. The metastatic tumors were resistant to chemotherapy and the patient suffered from severe bone marrow suppression. NGS of the whole exon revealed somatic mutations including 9666 single-nucleotide variants (SNVs) from 5148 genes, 55 copy number variations (CNVs), and 140 insertion–deletion variations. The high frequency of SNVs makes it distinguished case. However, no mutation of key tumor driver genes with functional significance was identified. No abnormality was found in nucleic acid synthesis enzymes. No amplification of c-Myc and n-Myc was found by fluorescence in situ hybridization (FISH). Both NGS and immunohistochemistry (IHC) analysis indicated that DNA mismatch repair (MMR) system was intact. Interventions: After initial diagnosis, the patient received combinational chemotherapy, which includes vindesine, an analogue of adriamycin suggested by NGS data, for 4 months. Radical section of the tumor together with the left kidney and the left adrenal gland was performed 5 months after diagnosis. Postsurgical chemotherapy protocols was similar with the previous. Outcomes: The patient died 2 years after initial diagnosis after 8 relapses following combinational chemotherapy. Lessons: This case of neuroblastoma is with pronounced somatic mutations but unidentified driver gene and therapeutic target. Although NGS is a potentially powerful tool to guide precision medicine, at current stage, its application in the clinic certainly has its limits. The underlying mechanism of the substantially increased SNV number, as well as the malignant behaviors of the tumor, is yet to be revealed.
机译:原理:神经母细胞瘤是儿童常见的腹部恶性肿瘤。化学耐药和复发的病例预后较差。遗传背景和抗性机制仍未阐明。下一代序列(NGS)正在成为揭示遗传背景并在肿瘤学研究以及临床实践中指导精密医学的流行工具。患者关注:在这里,我们报道了一名初诊时年龄为2岁8个月的男孩的神经母细胞瘤病例,在两个肺部都有多个转移部位。转移性肿瘤对化学疗法有抵抗力,患者遭受了严重的骨髓抑制。整个外显子的NGS揭示了体细胞突变,包括来自5148个基因的9666个单核苷酸变异(SNV),55个拷贝数变异(CNV)和140个插入-缺失变异。 SNV的高频率使其成为杰出的案例。然而,没有发现具有功能意义的关键肿瘤驱动基因的突变。在核酸合成酶中未发现异常。通过荧光原位杂交(FISH)未发现c-Myc和n-Myc的扩增。 NGS和免疫组织化学(IHC)分析均表明DNA错配修复(MMR)系统是完整的。干预措施:初步诊断后,患者接受了4个月的联合化疗,其中包括长春地辛(一种由NGS数据提示的阿霉素类似物)。诊断后5个月进行肿瘤的根治性切除,连同左肾和左肾上腺。术后化疗方案与以前的相似。结果:联合化疗后8次复发,患者在初步诊断后2年死亡。经验教训:这例神经母细胞瘤具有明显的体细胞突变,但未确定驱动基因和治疗靶标。尽管NGS是指导精密医学的潜在强大工具,但在当前阶段,其在临床中的应用肯定有其局限性。 SNV数量大幅增加的潜在机制以及肿瘤的恶性行为尚待揭示。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号